Acebilustat | CAS#943764-99-6 | leukotriene A4 hydrolase inhibitor

MedKoo Cat#: 319573 | Name: Acebilustat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acebilustat, also known as CTX4430; and ZK322, is a potent and selective leukotriene A4 hydrolase inhibitor. Acebilustat reduces the number of transmigrating neutrophils, while the metabolic modulator metformin decreases metabolism and oxidant production.

Chemical Structure

Acebilustat

CAS#943764-99-6

Theoretical Analysis

MedKoo Cat#: 319573

Name: Acebilustat

CAS#: 943764-99-6

Chemical Formula: C29H27N3O4

Exact Mass: 481.2002

Molecular Weight: 481.55

Elemental Analysis: C, 72.33; H, 5.65; N, 8.73; O, 13.29

Price and Availability

Size	Price	Availability
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks
100mg	USD 1,350.00	2 Weeks
200mg	USD 2,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZK322; ZK-322; ZK 322; CTX-4430; CTX4430; CTX 4430; EP501; EP-501; EP 501; Acebilustat;

IUPAC/Chemical Name

4-(((1S,4S)-5-(4-(4-(oxazol-2-yl)phenoxy)benzyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)benzoic acid

InChi Key

GERJIEKMNDGSCS-DQEYMECFSA-N

InChi Code

InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)/t24-,25-/m0/s1

SMILES Code

O=C(O)C1=CC=C(CN2[C@](C3)([H])CN(CC4=CC=C(OC5=CC=C(C6=NC=CO6)C=C5)C=C4)[C@]3([H])C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO, not in water	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 481.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bowman C, Rockson SG. Genetic causes of lymphatic disorders: recent updates on the clinical and molecular aspects of lymphatic disease. Curr Opin Cardiol. 2024 May 1;39(3):170-177. doi: 10.1097/HCO.0000000000001116. Epub 2024 Mar 13. PMID: 38483006. 2: Lim CS, Veltri B, Kashon M, Porter DW, Ma Q. Multi-walled carbon nanotubes induce arachidonate 5-lipoxygenase expression and enhance the polarization and function of M1 macrophages in vitro. Nanotoxicology. 2023 Apr;17(3):249-269. doi: 10.1080/17435390.2023.2204161. Epub 2023 Apr 28. PMID: 37115655; PMCID: PMC10263170. 3: Levitt JE, Hedlin H, Duong S, Lu D, Lee J, Bunning B, Elkarra N, Pinsky BA, Heffernan E, Springman E, Moss RB, Bonilla HF, Parsonnet J, Zamanian RT, Langguth JJ, Bollyky J, Khosla C, Nicolls MR, Desai M, Rogers AJ. Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jul 26;77(2):186-193. doi: 10.1093/cid/ciad187. PMID: 36996150; PMCID: PMC10517095. 4: Elborn JS, Konstan MW, Taylor-Cousar JL, Fajac I, Horsley A, Sutharsan S, Aaron SD, Daines CL, Uluer A, Downey DG, Lucidi VV, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM; EMPIRE-CF study group. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 Nov;20(6):1026-1034. doi: 10.1016/j.jcf.2021.08.007. Epub 2021 Sep 17. PMID: 34538755; PMCID: PMC8649042. 5: Currie AJ, Main ET, Wilson HM, Armstrong-James D, Warris A. CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes. Front Cell Infect Microbiol. 2020 Jul 24;10:372. doi: 10.3389/fcimb.2020.00372. PMID: 32793514; PMCID: PMC7393064. 6: Somayaji R, Nichols DP, Bell SC. Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. Expert Opin Investig Drugs. 2020 Oct;29(10):1107-1124. doi: 10.1080/13543784.2020.1805733. Epub 2020 Oct 10. PMID: 32744089. 7: Elborn JS, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM. EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics. Contemp Clin Trials. 2018 Sep;72:86-94. doi: 10.1016/j.cct.2018.07.014. Epub 2018 Jul 26. PMID: 30056216. 8: Forrest OA, Ingersoll SA, Preininger MK, Laval J, Limoli DH, Brown MR, Lee FE, Bedi B, Sadikot RT, Goldberg JB, Tangpricha V, Gaggar A, Tirouvanziam R. Frontline Science: Pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis. J Leukoc Biol. 2018 Oct;104(4):665-675. doi: 10.1002/JLB.5HI1117-454RR. Epub 2018 May 9. PMID: 29741792; PMCID: PMC6956843. 9: Erratum to "Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction". Clin Transl Sci. 2018 Jan;11(1):93. doi: 10.1111/cts.12510. Erratum for: Clin Transl Sci. 2017 Jan;10(1):20-27. doi: 10.1111/cts.12426. PMID: 29314733; PMCID: PMC5759731. 10: Elborn JS, Horsley A, MacGregor G, Bilton D, Grosswald R, Ahuja S, Springman EB. Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2017 Jan;10(1):28-34. doi: 10.1111/cts.12428. Epub 2016 Nov 2. PMID: 27806191; PMCID: PMC5351012. 11: Elborn JS, Bhatt L, Grosswald R, Ahuja S, Springman EB. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2017 Jan;10(1):20-27. doi: 10.1111/cts.12426. Epub 2016 Oct 28. Erratum in: Clin Transl Sci. 2018 Jan;11(1):93. doi: 10.1111/cts.12510. PMID: 27792868; PMCID: PMC5351008.